Challenges in development of nanoparticle-based therapeutics

AAPS Journal

Volumn 14, Issue 2, 2012, Pages 282-295

  Desai, Neil ^a  

^a A Wholly Owned Subsidiary of Celgene Corporation   (United States)

Author keywords

Biodistribution; Immune toxicity; Nab paclitaxel; Nanoparticle; Pharmacokinetics

Indexed keywords

CELL PENETRATING PEPTIDE; CREMOPHOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FERUMOXYTOL; LIPOSOME; MACROGOL; NANOPARTICLE; PACLITAXEL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANAPHYLAXIS; BLOOD BRAIN BARRIER; BREAST METASTASIS; CARDIOTOXICITY; DRUG ACCUMULATION; DRUG APPROVAL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; DRUG TARGETING; DRUG TUMOR LEVEL; HAND FOOT SYNDROME; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NANOMEDICINE; NONHUMAN; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; QUALITY CONTROL; REVIEW; TRANSCYTOSIS; TUMOR VASCULARIZATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; NANOMEDICINE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84860722540     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9339-4     Document Type: Review

References (96)

1. Emerich DF, Thanos CG. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol Eng. 2006;23(4):171-84. (Pubitemid 44142336)
2. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed Pharmacother Biomed Pharmacother. 2004;58 (3):168-72. (Pubitemid 38479921)
3. Silva GA. Nanotechnology approaches to crossing the blood- brain barrier and drug delivery to the CNS. BMC Neurosci. 2008;9 Suppl 3:S4.
4. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res. 2003;20(9):1337-50. (Pubitemid 37164040)
5. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74(1-3):47-61. (Pubitemid 32727608)
6. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987;6(4):559-93.
7. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497-503. (Pubitemid 30262444)
8. Dong X, Mumper RJ. Nanomedicinal strategies to treat multi-drug-resistant tumors: current progress. Nanomedicine (London, England). 2010;5(4):597-615.
9. Greish K. Enhanced permeability and retention of macromolec-ular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007;15(7-8):457-64. (Pubitemid 47209047)
10. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60 (8):876-85.
11. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-8. (Pubitemid 32778603)
12. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263-8. (Pubitemid 20195638)
13. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19 (2):125-41. (Pubitemid 32423718)
14. Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton). 2005;10(3):317-20. (Pubitemid 40910382)
15. Lammers T, Hennink WE, Storm G. Tumour-targeted nano-medicines: principles and practice. Br J Cancer. 2008;99(3):392-7.
16. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2(10):750-63. (Pubitemid 37328910)
17. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006;6(9):688-701. (Pubitemid 44286001)
18. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57(4):637-51. (Pubitemid 40255564)
19. Holig P, Bach M, Volkel T, Nahde T, Hoffmann S, Muller R, et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng Des Sel. 2004;17(5):433-41. (Pubitemid 39280045)
20. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release. 2003;91(1-2):115-22. (Pubitemid 37288882)
21. Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, et al. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release. 2009;140(2):166-73.
22. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res. 2006;12(4):1317-24. (Pubitemid 43342524)
23. Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine-an overview. Fundam Clin Pharmacol. 2009;23 (3):263-9.
24. Moghimi SM, Hunter AC, Murray JC Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283-318.
25. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1-9. (Pubitemid 351467152)
26. Douglas SJ, Davis SS, Illum L. Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst. 1987;3(3):233-61. (Pubitemid 17021225)
27. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55 (17):3752-6.
28. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 1998;95(8):4607-12. (Pubitemid 28207960)
29. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57-64.
30. Moghimi SM. Modulation of lymphatic distribution of subcuta-neously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett. 2003;540 (1-3):241-4. (Pubitemid 36398064)
31. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463-78. (Pubitemid 37237636)
32. Gessner A, Waicz R, Lieske A, Paulke B, Mader K, Muller RH. Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm. 2000;196 (2):245-9. (Pubitemid 30105753)
33. Gigli I, Nelson Jr RA. Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res. 1968;51(1):45-67.
34. Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res. 2006;23(6):1313-23. (Pubitemid 43946153)
35. Lasic DD. Doxorubicin in sterically stabilized liposomes. Nature. 1996;380(6574):561-2.
36. Huang YF, Liu H, Xiong X, Chen Y, Tan W. Nanoparticle-mediated IgE-receptor aggregation and signaling in RBL mast cells. J Am Chem Soc. 2009;131(47):17328-34.
37. Irvine DJ. Drug delivery: one nanoparticle, one kill. Nat Mater. 2011;10(5):342-3.
38. Bandyopadhyay A, Fine RL, Demento S, Bockenstedt LK, Fahmy TM. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials. 2011;32(11):3094-105.
39. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-9. (Pubitemid 38444547)
40. Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, et al. Role of complement activation in hypersensitivity reactions to Doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res. 2002;12(1-2):165-72. (Pubitemid 34846969)
41. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15(10):1527-34. (Pubitemid 39409744)
42. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf. 2001;24 (12):903-20. (Pubitemid 33078196)
43. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11(4):413-24. (Pubitemid 38294346)
44. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004;58(4):1215-27. (Pubitemid 38314807)
45. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006;103 (16):6315-20.
46. Rovira-Bru M, Thompson DH, Szleifer I. Size and structure of spontaneously forming liposomes in lipid/PEG-lipid mixtures. Biophys J. 2002;83(5):2419-39. (Pubitemid 35265738)
47. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly (ethylene glycol). Biosci Rep. 2002;22(2):225-50. (Pubitemid 35222733)
48. Zhu J, Xue J, Guo Z, Marchant RE. Vesicle size and stability of biomimetic liposomes from 3′-sulfo-Lewis a (SuLea) containing glycolipids. Colloids Surf B: Biointerfaces. 2007;58(2):242-9. (Pubitemid 46921463)
49. FDA. Guidance for Industry: Liposome Drug Products. 2002. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ucm070570.pdf.
50. Özcan I, Bouchemal K, Segura-Sánchez F, Abaci Ö, Özer Ö, Güneri T, et al. Effects of sterilization techniques on the PEGylated poly (γ-benzyl-L-glutamate) (PBLG) nanoparticles. Acta Pharm Sci. 2009;51:211-8.
51. Bozdag S, Dillen K, Vandervoort J, Ludwig A. The effect of freeze-drying with different cryoprotectants and gamma-irradiation sterilization on the characteristics of ciprofloxacin HCl-loaded poly(D, L-lactide-glycolide) nanoparticles. J Pharm Pharmacol. 2005;57(6):699-707. (Pubitemid 40694877)
52. Kempner ES. Effects of high-energy electrons and gamma rays directly on protein molecules. J Pharm Sci. 2001;90 (10):1637-46. (Pubitemid 32979758)
53. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009;6(3):659-68.
54. Eifler AC, Thaxton CS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol. 2011;726:325-38.
55. Shi Y, Zhou L, Wang R, Pang Y, Xiao W, Li H, et al. In situ preparation of magnetic nonviral gene vectors and magneto-fection in vitro. Nanotechnology. 2010;21(11):115103.
56. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622-7. (Pubitemid 43191298)
57. Song Y, Li X, Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J. 2009;34(3):559-67.
58. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-53. (Pubitemid 43949942)
59. Merisko-Liversidge E, Sarpotdar P, Bruno J, Hajj S, Wei L, Peltier N, et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res. 1996;13(2):272-8. (Pubitemid 26074194)
60. Lin W, Coombes AG, Davies MC, Davis SS, Illum L. Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. J Drug Target. 1993;1(3):237-43.
61. Muller BG, Leuenberger H, Kissel T. Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm Res. 1996;13(1):32-7. (Pubitemid 26076293)
62. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003;257(1-2):169-80. (Pubitemid 36507043)
63. FDA. Draft Guidance on Doxorubicin Hydrochloride. 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM199635.pdf.
64. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008;13(3):248-60. (Pubitemid 351679900)
65. Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2003;89(3):237-49. (Pubitemid 37014112)
66. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11(11):4136-43. (Pubitemid 40791578)
67. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299-319.
68. Kim KJ, Malik AB. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol. 2003;284(2):L247-59. (Pubitemid 36164359)
69. Newman GR, Campbell L, von Ruhland C, Jasani B, Gumbleton M. Caveolin and its cellular and subcellular immunolocalisation in lung alveolar epithelium: implications for alveolar epithelial type I cell function. Cell Tissue Res. 1999;295(1):111-20. (Pubitemid 29011944)
70. Desai N, De T, Yang A, Beals B, Soon-Shiong P, editors. Pulmonary delivery of novel, Cremophor-free, protein-based nanoparticle preparation of paclitaxel. In Proceedings of the 94th American Association for Cancer Research Annual Meeting (AACR), Washington, DC, 11-14. AACR. 2003
71. Vines T, Faunce T. Assessing the safety and cost-effectiveness of early nanodrugs. J Law Med. 2009;16(5):822-45.
72. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. Endocrinology. 2010;151(2):458-65.
73. FDA Nanotechnology Task Force. Nanotechnology Task Force Report 2007. 2007. http://www.fda.gov/scienceresearch/specialtopics/nanotechnology/ nanotechnologytaskforcereport2007/default.htm.
74. ISO. ISO/IEC/NIST/OECD Workshop: FINAL REPORT June 2008. ISO, IEC, NIST and OECD International workshop on documentary standards for measurement and characterization for nanotechnologies 2008 02/26-02/28/2008; Gaithersburg, Maryland, USA. 2008.
75. Trynda-Lemiesz L. Paclitaxel-HSA interaction. Binding sites on HSA molecule. Bioorg Med Chem. 2004;12(12):3269-75. (Pubitemid 38680716)
76. Braden BC, Goldbaum FA, Chen BX, Kirschner AN, Wilson SR, Erlanger BF. X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: biomolecular recognition of C(60). Proc Natl Acad Sci U S A. 2000;97 (22):12193-7.
77. Chen BX, Wilson SR, Das M, Coughlin DJ, Erlanger BF. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. Proc Natl Acad Sci U S A. 1998;95 (18):10809-13. (Pubitemid 28413150)
78. Lee SC, Parthasarathy R, Botwin K, Kunneman D, Rowold E, Lange G, et al. Biochemical and immunological properties of cytokines conjugated to dendritic polymers. Biomed Microdevices. 2004;6(3):191-202. (Pubitemid 39256165)
79. Wang Y. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011 (in press).
80. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2(8):469-78. (Pubitemid 47220069)
81. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008;5(4):487-95.
82. Abrams MT, Koser ML, Seitzer J, Williams SC, Dipietro MA, Wan g W, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2009;18:171-80.
83. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm. 2008;354(1-2):56-62.
84. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349-55. (Pubitemid 47407760)
85. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119(2):236-44. (Pubitemid 46759557)
86. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003;14 (9):1430-7. (Pubitemid 37185291)
87. Sloat BR, Sandoval MA, Hau AM, He Y, Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J Control Release. 2010;141(1):93-100.
88. Kreuter J. Nanoparticles as adjuvants for vaccines. Pharm Biotechnol. 1995;6:463-72.
89. Domanski DM, Klajnert B, Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectro-chemistry. 2004;63(1-2):189-91. (Pubitemid 38534218)
90. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000;65(1-2):133-48. (Pubitemid 30122922)
91. Bosi S, Feruglio L, Da Ros T, Spalluto G, Gregoretti B, Terdoslavich M, et al. Hemolytic effects of water-soluble fullerene derivatives. J Med Chem. 2004;47(27):6711-5. (Pubitemid 40053760)
92. Cohen JJ. Apoptosis: the physiologic pathway of cell death. Hosp Pract (Off Ed). 1993;28(12):35-43. (Pubitemid 24006313)
93. Schroit AJ, Madsen JW, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem. 1985;260(8):5131-8. (Pubitemid 15031516)
94. Greish K, Thiagarajan G, Herd H, Price R, Bauer H, Hubbard D, et al. Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology. 2011 Jul 28.
95. EMA. 1st International Workshop on Nanomedicines 2010 Summary Report. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2010/10/ WC500098380.pdf.
96. FDA. Draft Guidance: considering whether an FDA-Regulated product involves the application of nanotechnology. 2011. http://www.fda.gov/ RegulatoryInformation/Guidances/ucm257698.htm.